Welcome to our dedicated page for Purple Biotech SEC filings (Ticker: PPBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Purple Biotech Ltd. (PPBT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Purple Biotech files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with registration statements on Forms F-1, F-3 and S-8, outline the company’s clinical-stage oncology strategy, financing activities, and corporate actions.
Through its Form 6-K reports, Purple Biotech furnishes press releases and corporate presentations that describe its oncology pipeline, including the CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219. Filings reference milestones such as manufacturing achievements for IM1240, preclinical and clinical data updates, European patent developments for NT219 combinations, and collaborations with academic institutions. They also include financial results, at-the-market offering agreements, and details of public offerings of American Depositary Shares and warrants.
Investors use Purple Biotech’s SEC filings to review quarterly and interim financial information furnished on Form 6-K, as well as capital markets transactions such as shelf registrations on Form F-3 and follow-on offerings. The filings also document corporate governance events, including notices and results of shareholder meetings, and incorporate certain reports by reference into existing registration statements.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify information on pipeline progress, financing terms, and listing compliance matters. Users can follow new 6-K submissions in near real time as they are posted to EDGAR, and then drill into specific exhibits such as press releases or corporate presentations for more detail.
For those researching PPBT, this page serves as a central location to review Purple Biotech’s official SEC communications related to its clinical programs, financial position, and securities offerings, all organized chronologically with concise AI-generated overviews.
Purple Biotech Ltd. entered into a new at-the-market equity offering agreement with H.C. Wainwright & Co., LLC, allowing it to sell American Depositary Shares (ADSs), each representing 200 ordinary shares, from time to time through Wainwright as agent. These sales will be made under an existing Form F-3 shelf registration statement, with a prospectus supplement that permits ADS sales of up to an aggregate offering price of $2,300,000.
The company also terminated its prior at-the-market program with Jefferies LLC, which had been in place since 2021. Under the Jefferies program, Purple Biotech sold 983,317 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS. The 6-K and its exhibits are incorporated by reference into multiple existing registration statements.
Purple Biotech Ltd. (PPBT) is a clinical-stage pharmaceutical company focused on oncology candidates including NT219, CM24 and IM1240. The prospectus supplement outlines ongoing and planned clinical programs, collaborations, capitalization items and offering mechanics. NT219 completed a Phase 1 dose-escalation study showing anti-tumor activity in recurrent/metastatic head and neck cancer and an investigator-initiated Phase 2 study with University of Colorado was initiated in June 2025. CM24 is in a randomized open-label Phase 2 study in pancreatic ductal adenocarcinoma in collaboration with Bristol Myers Squibb, with interim data expected in the second half of 2023 and topline by end of 2024. The company completed corporate actions changing ADS ratios and a 1:20 share consolidation in 2019. Financing programs include a Sales Agreement with Jefferies for up to USD 50,000,000 and various warrants and ADS offerings. The filing emphasizes significant risks: operating losses, need for additional capital, reliance on third parties for manufacturing and trials, regulatory uncertainty and IP and geopolitical risks.
Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer to furnish an updated corporate presentation titled “Purple Biotech Corporate presentation September 2025.” The presentation is attached as Exhibit 99.1. The company states that this Form 6-K, including all exhibits, is incorporated by reference into multiple existing registration statements on Forms S-8, F-3 and F-1, with specified SEC file numbers. This means the updated presentation now forms part of those registration statements from the date this report is submitted, unless later filings supersede it.
Purple Biotech Ltd. received a joint Schedule 13G from Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reporting shared beneficial ownership of 139,632,475 ordinary shares, representing 9.99% of the class as of September 10, 2025. The filing explains those shares include issued shares and shares issuable on exercise of two warrants, but each warrant contains a blocker provision preventing exercise that would increase beneficial ownership above 9.99%. The reporting persons state the holdings were not acquired to change or influence issuer control and filed a joint filing agreement.
Purple Biotech Ltd. filed a 6-K describing a new development for its NT219 drug candidate. The company received an intention to grant a European patent covering combinations of NT219 with immunotherapies or MEK inhibitors, aimed at overcoming tumor resistance. This update was communicated in a press release attached to the filing as Exhibit 99.1.
Purple Biotech Ltd. received a Schedule 13G from Lincoln Alternative Strategies LLC reporting beneficial ownership of 605,000 American Depositary Shares, equal to 9.94% of the class. Each ADS represents 200 ordinary shares, and the filing bases the percentage on 6,085,450 common shares outstanding as of Sept 4, 2025. Lincoln reports sole voting and dispositive power over all 605,000 ADS and certifies the position was not acquired to change or influence control. The filing is signed by Stephen Temes as Managing Member on Sept 9, 2025. The issuer's principal office is listed in Rehovot, Israel.
Purple Biotech Ltd.'s Schedule 13G/A filed by Orca Capital AG reports beneficial ownership of 306,394 American Depositary Shares (ADSs), representing 4.9% of the class on a post-offering basis. Each ADS represents 200 ordinary shares, and the ownership percentage is calculated using 6,085,450 ADSs outstanding after the issuer's registered offering.
The filing discloses that Orca has sole voting and dispositive power over all 306,394 ADSs and excludes 1,832,495 ADSs issuable upon exercise of Series B warrants held by Orca, which are subject to a 4.99% exercise blocker that prevents Orca from exercising warrants to exceed 4.99% ownership.
Purple Biotech Ltd. received a Schedule 13G filing from Orca Capital AG reporting beneficial ownership of 605,000 ADSs, representing 9.9% of the outstanding American Depositary Shares (based on 6,085,450 ADSs outstanding after the issuer's registered offering). Orca Capital states sole voting and dispositive power over these ADSs and files as a German reporting person. The filing notes that the Reporting Person holds additional pre-funded and Series B warrants that are subject to a 4.99% blocker, preventing exercise that would increase beneficial ownership above 4.99% of ordinary shares under the warrants' terms. The filing is certified by Thomas Konig, Director of Orca Capital AG.
Purple Biotech Ltd. filed a Form 6-K as a foreign private issuer, furnishing documents related to a planned financing. The exhibits include forms of a pre-funded warrant, a standard warrant, a placement agent warrant, and a securities purchase agreement, along with a press release titled “Purple Biotech Announces Pricing of Up To $18 Million Public Offering.” This indicates the company has set terms for a public offering involving ADSs and warrants.
The company states that this report does not itself constitute an offer to sell or solicit purchases of ADSs or warrants in any jurisdiction where such actions would be unlawful. The Form 6-K and its exhibits are also incorporated by reference into multiple existing Purple Biotech registration statements on Forms S-8, F-1, and F-3, making these offering documents part of those shelves and employee plan registrations.
Purple Biotech Ltd. is offering 3,055,000 ADSs (representing 611,000,000 Ordinary Shares) together with 6,110,000 Warrants to purchase up to 6,110,000 ADSs. The placement agent fee is 7.0% of gross proceeds, shown as $419,999.93, leaving estimated proceeds to the company of $5,579,704.57 before other offering expenses. The company estimates additional offering expenses (excluding placement agent fees) of approximately $215,000. Proceeds are intended to fund oncology therapeutic development and general corporate purposes. The prospectus discloses multiple historic and outstanding equity instruments and warrants with specified exercise prices and ADS equivalents, and states Ordinary Shares outstanding after this offering would be 1,806,089,801 assuming full exercise of the Pre-Funded Warrants and no exercise of the offered Warrants. The ADSs trade on Nasdaq under the symbol PPBT, and a 60-day director/officer lock-up applies. Clinical program details include NT219, with a Phase 2 investigator-initiated study initiated in June 2025.